BUSINESS: Selecta Biosciences Provides An Update On The Phase 1/2 Clinical Trial For SEL-302 To Treat Methylmalonic Acidemia

dWeb.News Article from Daniel Webster dWeb.News

by Daniel Webster, dWeb.News Publisher

-U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions-

November 24, 2021 16: 15 ET | Source: Selecta Biosciences, Inc.

WATERTOWN, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR(tm) platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its Phase 1/2 clinical trial of SEL-302 (which consists of MMA-101 plus ImmTOR) for the treatment of patients with methylmalonic acidemia (MMA).

On November 23, Selecta received a letter from the FDA issuing a clinical hold in order to obtain additional information on the chemistry, manufacturing and controls (CMC) related to the MMA-101 product candidate. The FDA letter did not contain any pre-clinical or clinical questions. This clinical trial had not yet been initiated, and no human patients will be dosed with MMA-101 until all of the FDA’s questions are resolved. Selecta will work closely with FDA to answer any additional questions.

“Patient safety is our primary concern, and we are committed to addressing the FDA’s questions regarding CMC as expeditiously as possible,” said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. “We look forward to working closely with the FDA to satisfy all outstanding concerns, and to providing additional updates early next year.”

About MMA
MMA is a rare metabolic disease that affects the body’s ability to metabolize certain amino acids and fats. This condition can lead to metabolic acidosis and hyperammonemia, as well as long-term complications such as feeding problems, intellectual disability, chronic kidney disease, and developmental delays.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. ImmTOR is a well-proven method to induce tolerance to immunogenic proteins. This can increase the effectiveness of biologic therapies and redo life-saving gene therapies. It can also restore the body’s natural self tolerance to autoimmune diseases. Selecta Biosciences has several programs that are both proprietary and partnered, which focus on gene therapies, enzyme therapies, and autoimmune disorders. Selecta Biosciences has its headquarters in Greater Boston. For more information, please visit

Selecta Forward-Looking Statements
Any statements in this press release about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the Company”), including without limitation, statements regarding the unique proprietary technology platform of the Company, and the unique proprietary platform of its partners, the programs and disease indication targets anticipated under this agreement, the ability of any drug candidate developed under the agreement to offer a therapeutic benefit, the potential of ImmTOR to enable re-dosing of AAV gene therapy, to enhance transgene expression and to mitigate immunogenicity, the potential treatment applications of product candidates utilizing the ImmTOR platform in areas such as gene therapy, the ability of the Company and its partners where applicable to develop gene therapy products using ImmTOR, the novelty of treatment paradigms that the Company is able to develop, the potential of the ImmTOR technology platform generally and the Company’s ability to grow its strategic partnerships, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the unproven approach of the Company’s ImmTOR technology, our partners’ ability to develop products under the agreement, undesirable side effects of the Company’s technology, its reliance on third parties to manufacture its product candidates and to conduct its development activities, the Company’s inability to maintain its existing or future collaborations, licenses or contractual relationships, its inability to protect its proprietary technology and intellectual property, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the Company’s recurring losses from operations and negative cash flows from operations raise substantial doubt regarding its ability to continue as a going concern, substantial fluctuation in the price of its common stock, and other important factors discussed in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K to be filed after this release, and in other filings that the Company makes with the Securities and Exchange Commission. Forward-looking statements in this press release are only current as of the date they were published and should not be regarded as representing the Company’s views at any future date.

Bruce Mackle90+1-65Brittany Leigh, Ph.D. _______

For Investors:
Bruce Mackle
LifeSci Advisors, LLC

For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC

For more dWeb.News Business News:

The post BUSINESS: Selecta Biosciences Provides An Update On The Phase 1/2 Clinical Trial For SEL-302 To Treat Methylmalonic Acidemia appeared first on dWeb.News dWeb.News from Daniel Webster Publisher dWeb.News – dWeb Local Tech News and Business News

dWeb.NewsRead More

Similar Posts